Push/Pull

Antibiotic procurement models for LMICs / G7 Leaders call for Pull!

Dear All, Two stops on our tour today: (i) an excellent survey of incentive models and (ii) a final communique from the recent G7 meetings. First up, CGD (Center for Global Development) have released a report (link) entitled “Leveraging Purchasing Systems to Ensure Access, Stewardship, and Innovation: A Landscape Review of Current and Potential Market Structures

Read More »

G7 Finance Ministers call for Pull; US-specific text cites PASTEUR and a PASTEUR backup plan!

https://www.youtube.com/watch?v=f0-xt3FrAGU&ab_channel=AMR.SolutionswithDr.JohnRex Dear All, VERY exciting news on the Pull incentive front: The G7 Finance Ministers have released a statement on Actions to Support Antibiotic Development, aiming to strengthen G7 preparedness against the “silent pandemic” of antimicrobial resistance. Implicitly, this is a statement that is agreed and endorsed by the political leadership of each country —

Read More »

Updated ATMF AMR Benchmark! Signs of progress but access lags

Dear All (and with thanks to ATMF’s Damiano de Felice for co-authoring this newsletter), Last week, the team at ATMF (Access to Medicine Foundation) released a 3rd update to the AMR Benchmark series that they started in 2018. For those not familiar with the ATMF, its independent analyses (all its funding is from governments or private

Read More »

Pull incentives for antibiotics: How much and why? — A literature survey

Dear All (and with thanks to Kevin Outterson for co-authoring this newsletter), The recent discussions of the NICE/NHS England pilot subscription model (detailed newsletter plus follow-up FAQ newsletter) and a new paper by Chantal Morel and colleagues on the idea of an Antibiotic Susceptibility Bonus (ASB, link) bring to the fore the question of how to value any given

Read More »

Woot, woot! Cures 2.0 introduced; PASTEUR Act is a key feature!

Dear All, Following release back in June of a preview (22 June 2021 newsletter), we now have the official introduction of Cures 2.0 by the bipartisan team of U.S. Reps. Diana DeGette (D-CO) and Fred Upton (R-MI)! Here are the links you need: Cures 2.0 legislation is available here. Section-by-section summary of the bill is available here. There

Read More »

Building momentum for delinked incentives: Key upcoming webinars

Dear All, A brief note today as I am traveling (yes, really … first time in almost 18 months) but wanted to share these 3 important upcoming meetings. The theme I expect to hear running through them all is that (i) innovation is possible (the CARB-X Year 5 report is amazing!), (ii) new antibiotics must both

Read More »

Antibiotic supply chains: Challenges & Opportunities

Dear All, In a report entitled Understanding the Antibiotic Manufacturing Ecosystem: A view of global supply chains, pressure points, and implications for antimicrobial resistance response, the Boston Consulting Group and Wellcome Trust have examined at length the questions of (i) how the #FireExtinguishersOfMedicine are made and (ii) how they can be made with the least impact

Read More »

REVAMP, a pull incentive in the US: Time to make it happen!

Dear All: I previously wrote about the nascent REVAMP legislation that would create a Pull incentive in the US market. With everybody back from the July 4th holiday, the goal for this week is to get REVAMP into position to be offered as an amendment at the House Energy & Commerce Committee’s PAHPA mark-up (expected next week).

Read More »
Scroll to Top